Compare STKS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | BDSX |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.0M | 62.5M |
| IPO Year | N/A | 2020 |
| Metric | STKS | BDSX |
|---|---|---|
| Price | $2.06 | $5.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $32.50 |
| AVG Volume (30 Days) | 45.7K | ★ 72.0K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $820,588,000.00 | $80,173,000.00 |
| Revenue This Year | $25.10 | $20.75 |
| Revenue Next Year | $6.58 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 51.57 | 22.29 |
| 52 Week Low | $1.70 | $3.44 |
| 52 Week High | $5.26 | $31.00 |
| Indicator | STKS | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 31.72 |
| Support Level | $1.70 | $5.61 |
| Resistance Level | $2.29 | $6.92 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 59.32 | 9.10 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.